Valneva SE Sponsored ADR (NASDAQ:VALN) Given Average Recommendation of “Hold” by Brokerages

Shares of Valneva SE Sponsored ADR (NASDAQ:VALN) have been assigned a consensus recommendation of “Hold” from the five ratings firms that are currently covering the company, MarketBeat reports. Two analysts have rated the stock with a sell rating and three have assigned a buy rating to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $11.9750.

Several brokerages have commented on VALN. Guggenheim set a $11.00 target price on shares of Valneva in a research report on Thursday, April 16th. The Goldman Sachs Group lowered shares of Valneva from a “neutral” rating to a “sell” rating and set a $4.90 target price on the stock. in a research report on Wednesday, April 22nd. Finally, Wall Street Zen upgraded shares of Valneva from a “strong sell” rating to a “sell” rating in a research report on Monday, June 1st.

Valneva Price Performance

Shares of NASDAQ VALN opened at $5.26 on Thursday. The firm has a market capitalization of $499.12 million, a P/E ratio of -2.81 and a beta of 1.75. Valneva has a one year low of $5.06 and a one year high of $12.25. The company’s fifty day moving average is $5.82 and its two-hundred day moving average is $8.18. The company has a debt-to-equity ratio of 2.14, a quick ratio of 1.60 and a current ratio of 2.14.

Valneva (NASDAQ:VALN) last issued its earnings results on Tuesday, March 31st. The company reported ($0.42) EPS for the quarter. The company had revenue of $35.77 million for the quarter. Valneva had a negative return on equity of 107.63% and a negative net margin of 88.87%. Analysts forecast that Valneva will post -1 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. acquired a new position in shares of Valneva during the 4th quarter worth $44,000. Marex Group plc acquired a new position in shares of Valneva during the 2nd quarter worth $64,000. XTX Topco Ltd acquired a new position in shares of Valneva during the 4th quarter worth $94,000. VSM Wealth Advisory LLC raised its stake in shares of Valneva by 125.0% during the 3rd quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company’s stock worth $110,000 after buying an additional 5,000 shares during the last quarter. Finally, JPMorgan Chase & Co. acquired a new position in shares of Valneva during the 3rd quarter worth $124,000. Institutional investors and hedge funds own 11.39% of the company’s stock.

About Valneva

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.